Global Novel Drug Delivery Systems Market Growth (Status and Outlook) 2023-2029

Global Novel Drug Delivery Systems Market Growth (Status and Outlook) 2023-2029

Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.

Advantages of Novel Drug Delivery System are: Optimum dose at the right time and right location, efficient use of expensive drugs, excipients and reduction in production cost, Beneficial to patients, better therapy, improved comfort and standard of living.

LPI (LP Information)' newest research report, the “Novel Drug Delivery Systems Industry Forecast” looks at past sales and reviews total world Novel Drug Delivery Systems sales in 2022, providing a comprehensive analysis by region and market sector of projected Novel Drug Delivery Systems sales for 2023 through 2029. With Novel Drug Delivery Systems sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Novel Drug Delivery Systems industry.

This Insight Report provides a comprehensive analysis of the global Novel Drug Delivery Systems landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Novel Drug Delivery Systems portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Novel Drug Delivery Systems market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Novel Drug Delivery Systems and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Novel Drug Delivery Systems.

The global Novel Drug Delivery Systems market size is projected to grow from US$ 23770 million in 2022 to US$ 26870 million in 2029; it is expected to grow at a CAGR of 1.8% from 2023 to 2029.

Global Novel Drug Delivery Systems key players include Amgen, Teva, Roche, UCB (Union Chimique Belge), etc. Global top four manufacturers hold a share over 40%.

North America is the largest market, with a share about 50%, followed by Asia-Pacific and Europe, both have a share over 40 percent.

In terms of product, PEGylated Proteins & Polypeptides is the largest segment, with a share about 40%. And in terms of application, the largest application is Hospitals & Clinic, followed by Cancer Treatment Centers, etc.

This report presents a comprehensive overview, market shares, and growth opportunities of Novel Drug Delivery Systems market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Liposomes

PEGylated Proteins & Polypeptides

Polymer Nanoparticle

Protein–drug Conjugates

Others

Segmentation by application

Hospitals & Clinic

Cancer Treatment Centers

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Amgen

Teva

Roche

UCB (Union Chimique Belge)

Celgene

Merck

Gilead Sciences

Sanofi

Pfizer

Takeda

Bausch&Lomb

Samyang Biopharmaceuticals

Johnson & Johnson

TOLMAR

Astellas

AMAG Pharmaceuticals

AbbVie

Dr Reddy

AstraZeneca

Aspen

Acrotech Biopharma

TWi Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.